Novonesis stock analysis
Novonesis (NZM) Stock Price & Analysis
NZM Stock Chart & Stats
- Day’s Range
- EUR 60.50 - EUR 60.50
- 52-Week Range
- EUR 44.80 - EUR 64.00
- Previous Close
- EUR 60.50
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 28.62B
- Enterprise Value
- EUR 32.86B
- Total Cash (Recent Filing)
- EUR 465.50M
- Total Debt (Recent Filing)
- EUR 3.18B
- Price to Earnings (P/E)
- 40.9
- Beta
- 0.33
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 0.59
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.22%
Bulls Say, Bears Say
Bulls Say
Diversified Market Position
Balanced exposure across geographies and multiple end markets reduces dependence on any single customer cycle or sector. This diversification can make revenue more resilient through uneven demand, while Novonesis can redirect innovation and commercial focus toward stronger structural growth areas.
Strong Operating Margins And Cash Generation
High operating margins and positive, growing operating cash flow indicate that Novonesis converts differentiated biosolutions and pricing into meaningful internal funding. This supports continued research, customer support, capacity investment and balance-sheet management without relying solely on external capital.
Innovation And Technology Expansion
A sustained biosolutions launch cadence strengthens Novonesis’s ability to address healthier products, higher yields and more efficient production. Continued innovation can deepen customer integration, expand applications for its technology platforms and support durable growth beyond existing product demand.
Bears Say
Recent Net Loss And Earnings Quality
The divergence between healthy operating margins and a recent net loss signals pressure below the operating line and reduces confidence in earnings consistency. If this persists, it could weaken retained capital, constrain shareholder returns and make reported profitability less dependable over coming quarters.
Delayed North American Supplements Recovery
Weakness in North American dietary supplements is more than a single-quarter fluctuation because management has pushed the expected recovery into the second half of 2027. Continued declines and customer destocking can weigh on Human Health growth and leave the portfolio dependent on other divisions for momentum.
High Investment Burden And FCF Pressure
Elevated capital expenditure and weaker free cash flow reduce near-term financial flexibility even while the projects may support future capacity. The burden is expected to continue into 2027, potentially limiting cash available for acquisitions, buybacks, debt reduction or other shareholder-oriented uses.
Novonesis News
NZM FAQ
What was Novonesis’s price range in the past 12 months?
What is Novonesis’s market cap?
When is Novonesis’s upcoming earnings report date?
How were Novonesis’s earnings last quarter?
Is Novonesis overvalued?
Does Novonesis pay dividends?
What is Novonesis’s EPS estimate?
How many shares outstanding does Novonesis have?
What happened to Novonesis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Novonesis?
What is the TipRanks Smart Score and how is it calculated?
Novonesis Stock Smart Score
Company Description
Novonesis
Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Basicmaterials
- Industry
- Chemicals - Specialty
- CEO
- Ester Baiget
- Employees
- 11,641
- Website
- www.novonesis.com
- Address
- Biologiens Vej 2, Lyngby, ND, 2800, DK
Novonesis (NZM) Earnings & Revenues
NZM Company Deck
NZM Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Novonesis reported solid 7% organic growth, strong margins, broad-based Food & Beverages and Energy momentum, continued innovation, completed strategic investments and confirmed its full-year outlook. The main challenges were the North American dietary supplements downturn, declines in Plant and Tech, elevated CapEx and lower free cash flow, but management expressed confidence in recovery initiatives and the long-term growth trajectory.
View all DE:NZM earnings summariesNZM Net sales Breakdown
- 28.53% Household Care
- 24.83% Bioenergy
- 22.07% Food, Beverages & Human Health
- 12.82% Grain & Tech Processing
- 11.75% Agriculture & Animal Health
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 10 | 0 | 2 |











